Gali Health offers an AI-based personalized health assistant and a diagnostic "Healthomes" platform used for therapeutic discovery by analyzing population-level health, lifestyle and genomic information. The company is primarily focused on research and development and is developing novel diagnostics and therapeutics both independently and in partnership with pharmaceutical companies. Gali was designed with input from IBD patient advocates and has a partnership with the Northern California Chapter of the Crohn’s and Colitis Foundation to advance education and support. The startup aims to grow its patient community to millions worldwide beyond IBD and to acquire biological samples for sequencing. Gali employs around seven staffers and said it plans to raise a significant financing round from institutional investors in the near future. The company was founded in 2016 by Ilya Kupershmidt, who previously sold NextBio to Illumina and provided scientific and technical leadership at Illumina. Gali Health is a San Francisco, CA–based health tech company that advances precision medicine by crowdsourcing personal health data and medically-validated insights. It applies AI to those data to provide personalized informational support on the medical, lifestyle and psychological aspects of living with chronic disease. The company's mobile personal health assistant, Gali, leverages individual health information and collective intelligence to allow people with chronic conditions to proactively manage their health. The assistant is currently available to a broader initial group of users who live with inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. The company raised over $2 million in seed funding to accelerate development and precision medicine–focused R&D efforts. Gali Health plans to release the intelligent health assistant to the general public in the fall of 2019.

Total raised

$5M

Funding rounds

2

Latest round

Seed

Latest activity

May 2020